Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, Gati Mirembe B, Mhlanga F, Hunidzarira P, Mansoor LE, Siva S, Govender V, Makanani B, Naidoo L, Singh N, Nair G, Chinula L, Parikh UM, Mellors JW, Balán IC, Ngure K, van der Straten A, Scheckter R, Garcia M, Peda M, Patterson K, Livant E, Bunge K, Singh D, Jacobson C, Jiao Y, Hendrix CW, Chirenje ZM, Nakabiito C, Taha TE, Jones J, Torjesen K, Nel A, Rosenberg Z, Soto-Torres LE, Hillier SL, Brown ER; MTN-025/HOPE Study Team. Baeten JM, et al. Among authors: mellors jw. Lancet HIV. 2021 Feb;8(2):e87-e95. doi: 10.1016/S2352-3018(20)30304-0. Lancet HIV. 2021. PMID: 33539762 Free PMC article. Clinical Trial.
Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.
Steytler J, Craig C, van der Ryst E, Van Baelen B, Nuttall J, van Niekerk N, Mellors J, Parikh U, Wallis C; Ring Study and the DREAM Trial Study Teams. Steytler J, et al. Clin Infect Dis. 2023 Mar 21;76(6):996-1002. doi: 10.1093/cid/ciac875. Clin Infect Dis. 2023. PMID: 36345569 Clinical Trial.
Global HIV control: is the glass half empty or half full?
Nachega JB, Musoke P, Kilmarx PH, Gandhi M, Grinsztejn B, Pozniak A, Rawat A, Wilson L, Mills EJ, Altice FL, Mellors JW, Quinn TC. Nachega JB, et al. Among authors: mellors jw. Lancet HIV. 2023 Sep;10(9):e617-e622. doi: 10.1016/S2352-3018(23)00150-9. Epub 2023 Jul 25. Lancet HIV. 2023. PMID: 37506723 Free PMC article. Review.
Brief Report: HIV Drug Resistance Assessment Among Women Who Seroconverted During the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial.
Parikh UM, Penrose KJ, Heaps AL, Sethi R, Goetz BJ, Szydlo D, Chandran U, Palanee-Phillips T, Mgodi NM, Baeten JM, Mellors JW; MTN-025/HOPE Study Team. Parikh UM, et al. Among authors: mellors jw. J Acquir Immune Defic Syndr. 2024 Jan 1;95(1):35-41. doi: 10.1097/QAI.0000000000003308. J Acquir Immune Defic Syndr. 2024. PMID: 37732881 Clinical Trial.
Long-acting antiretrovirals and HIV treatment adherence.
Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, Nachman S, Decloedt E, Geng EH, Wilson L, Rawat A, Mellors JW. Nachega JB, et al. Among authors: mellors jw. Lancet HIV. 2023 May;10(5):e332-e342. doi: 10.1016/S2352-3018(23)00051-6. Epub 2023 Apr 14. Lancet HIV. 2023. PMID: 37062293 Free PMC article. Review.
Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody Therapy.
Jacobs JL, Haidar G, Naqvi A, McCormick KD, Sobolewski M, Treat BR, Heaps AL, Simpson J, Kramer KH, McCreary E, Bariola JR, Klamar-Blain C, Macatangay BJC, Dimitrov D, Li W, Marino CC, Raptis A, Sethi R, Chandran U, Barratt-Boyes S, Parikh UM, Mellors JW. Jacobs JL, et al. Among authors: mellors jw. Open Forum Infect Dis. 2023 May 17;10(5):ofad278. doi: 10.1093/ofid/ofad278. eCollection 2023 May. Open Forum Infect Dis. 2023. PMID: 37265667 Free PMC article.
Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.
Haidar G, Hodges JC, Bilderback A, Lukanski A, Linstrum K, Postol B, Troyan R, Wisniewski MK, Coughenour L, Heaps A, Jacobs JL, Hughes Kramer K, Klamar-Blain C, Kohl J, Liang W, Morris B, Macatangay BJC, Parikh UM, Sobolewksi MD, Musgrove C, Crandall MD, Mahon J, Mulvey K, Collins K, King AC, Wells A, Zapf R, Agha M, Minnier T, Angus DC, Mellors JW. Haidar G, et al. Among authors: mellors jw. J Infect Dis. 2023 Nov 16:jiad511. doi: 10.1093/infdis/jiad511. Online ahead of print. J Infect Dis. 2023. PMID: 37972260
Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy.
Gandhi RT, Bosch RJ, Mar H, Laird GM, Halvas EK, Hovind L, Collier AC, Riddler SA, Martin A, Ritter K, McMahon DK, Eron JJ, Cyktor JC, Mellors JW; AIDS Clinical Trials Group A5321 Team. Gandhi RT, et al. Among authors: mellors jw. J Infect Dis. 2023 Jun 15;227(12):1376-1380. doi: 10.1093/infdis/jiad039. J Infect Dis. 2023. PMID: 36763044 Free PMC article.
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.
Haidar G, Jacobs JL, Kramer KH, Naqvi A, Heaps A, Parikh U, McCormick KD, Sobolewski MD, Agha M, Bogdanovich T, Bushunow V, Farah R, Hensley M, Hsu YS, Johnson B, Klamar-Blain C, Kozar J, Lendermon E, Macatangay BJC, Marino CC, Raptis A, Salese E, Silveira FP, Leen AM, Marshall WL, Miller M, Patel B, Atillasoy E, Mellors JW. Haidar G, et al. Among authors: mellors jw. Clin Infect Dis. 2023 Sep 11;77(5):696-702. doi: 10.1093/cid/ciad233. Clin Infect Dis. 2023. PMID: 37078720 Free PMC article.
414 results